Optimization of initial tacrolimus dose using pharmacogenetic testing (Q43099038)

13 November 2017

Optimization of initial tacrolimus dose using pharmacogenetic testing (English)

1 reference

13 November 2017

2

1 reference

13 November 2017

11

1 reference

13 November 2017

P Beaune

15

0 references

Markus Büchler

4

object named as

M Buchler

1 reference

13 November 2017

E Thervet

1

1 reference

13 November 2017

S Barbier

3

1 reference

13 November 2017

M Ficheux

5

1 reference

13 November 2017

G Choukroun

6

1 reference

13 November 2017

O Toupance

7

1 reference

13 November 2017

G Touchard

8

1 reference

13 November 2017

C Alberti

9

1 reference

13 November 2017

P Le Pogamp

10

1 reference

13 November 2017

Y Le Meur

12

1 reference

13 November 2017

A E Heng

13

1 reference

13 November 2017

J F Subra

14

1 reference

13 November 2017

C Legendre

16

1 reference

13 November 2017

language of work or name

English

0 references

publication date

14 April 2010

1 reference

Clinical Pharmacology & Therapeutics

13 November 2017

1 reference

13 November 2017

87

1 reference

13 November 2017

721-726

1 reference

13 November 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1038/clpt.2010.17

13 November 2017

0 references

cites work

Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.17

Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.17

Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.17

CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.17

The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.17

Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.17

Tacrolimus Dosing in Pediatric Heart Transplant Patients is Related to CYP3A5 and MDR1 Gene Polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.17

Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.17

The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.17

Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.17

Reduced exposure to calcineurin inhibitors in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.17

Genetic variability in CYP3A5 and its possible consequences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.17

The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.17

Pharmacokinetics of tacrolimus-based combination therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.17

Mechanisms of clinically relevant drug interactions associated with tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.17

Clinically significant drug interactions with new immunosuppressive agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.17

Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.17

Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.17

Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.17

CYP3A5 and ABCB1 Polymorphisms and Tacrolimus Pharmacokinetics in Renal Transplant Candidates: Guidelines from an Experimental Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.17

Low systemic exposure to tacrolimus correlates with acute rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.17

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CLPT.2010.17

1 reference

Dimensions Publication ID

13 November 2017

0 references

1 reference